SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Significant Increase in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 56,500 shares, a growth of 134.4% from the October 31st total of 24,100 shares. Based on an average daily trading volume, of 29,800 shares, the short-interest ratio is currently 1.9 days. Currently, 0.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Royal Bank of Canada reduced their price target on SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Morgan Stanley downgraded shares of SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $10.00 to $5.00 in a research note on Wednesday, August 7th.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH traded up $0.02 during trading on Thursday, reaching $3.27. 13,455 shares of the company’s stock were exchanged, compared to its average volume of 65,420. SOPHiA GENETICS has a fifty-two week low of $2.70 and a fifty-two week high of $7.37. The stock has a market capitalization of $213.79 million, a P/E ratio of -3.07 and a beta of 1.03. The business has a 50 day moving average price of $3.55 and a 200-day moving average price of $4.08. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The company had revenue of $15.85 million for the quarter, compared to analyst estimates of $15.90 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. During the same quarter in the prior year, the business posted ($0.21) EPS. Sell-side analysts forecast that SOPHiA GENETICS will post -0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors have recently made changes to their positions in SOPH. Banque Cantonale Vaudoise lifted its position in shares of SOPHiA GENETICS by 300.0% during the 2nd quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock valued at $55,000 after acquiring an additional 9,000 shares during the period. Green Alpha Advisors LLC bought a new position in SOPHiA GENETICS in the 3rd quarter valued at about $79,000. Federated Hermes Inc. raised its position in shares of SOPHiA GENETICS by 57.5% in the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after buying an additional 23,000 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of SOPHiA GENETICS by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after acquiring an additional 86,764 shares during the period. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.